Condition

MDS clinical trials and research

• 26Clinical trials
• 10Countries

Newest MDS clinical trials

All recruiting trials (26)

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• CG009301 for adults with relapsed or treatment‑resistant blood cancers

  This trial will try a new drug called CG009301 to see if it's safe and helps adults whose leukemia or related blood cancers have come back or not responded to prior treatment.

  Recruiting at 3 sites Phase 1 Cullgen (Shanghai),Inc · Nanchang and 2 other locations · NCT07347171

• Quality-of-life–guided red blood cell transfusions for people with refractory MDS or AML

  We test whether using routine EQ-5D-5L quality-of-life scores to decide when to give red blood cell transfusions can safely reduce the number of transfusions for adults with refractory MDS or AML who are receiving only palliative care.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice · NCT07328191

• High-altitude stem cell and bone marrow transplant registry on the Qinghai-Tibet Plateau

  This project will collect clinical data and blood/bone marrow samples from people having hematopoietic stem cell transplants on the Qinghai‑Tibet Plateau to see how high altitude affects transplant outcomes and recovery.

  Recruiting Affiliated Hospital of Qinghai University · Xining, Qinghai · NCT07205523

• A blood test to replace bone marrow exams for diagnosing cytopenias and MDS

  This study will test whether a blood test that analyzes circulating stem and progenitor cells can diagnose MDS and other unexplained low blood counts in adults referred for a bone marrow evaluation.

  Recruiting at 2 sites Weizmann Institute of Science · San Diego, California and 1 other locations · NCT07081087

• Oral tetrahydrouridine plus decitabine for relapsed or refractory MDS

  This trial tests a weekly oral combination of tetrahydrouridine and decitabine in adults with relapsed or refractory MDS to see if it is safe and reduces hospital days.

  Recruiting Phase 1 Treebough Therapies · The Bronx, New York · NCT07006025

• Long-term follow-up of TScan TCR-T therapies

  This follow-up will see if the TSC-100 and TSC-101 TCR-T therapies remain safe and continue to control disease over the long term in people who already received them.

  Recruiting at 2 sites TScan Therapeutics, Inc. · Duarte, California and 1 other locations · NCT06976736

• Using genetic information to guide maintenance therapy after stem cell transplantation for blood cancers

  This study is testing whether personalized treatment based on genetic information can help people with blood cancers like acute myeloid leukemia and myelodysplastic syndromes stay healthy after a stem cell transplant.

  Recruiting Phase 2/3 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06972641

• Comparing ATLG and ATG for immune recovery after allogeneic stem cell transplant

  This study will try using ATLG instead of ATG in adults receiving allogeneic stem cell transplants for blood cancers to see if immune recovery is faster and rates of viral infection or GVHD are lower.

  Recruiting Phase 2/3 Peking University First Hospital · Beijing · NCT06895538

• Ivosidenib maintenance after allogeneic stem cell transplant for IDH1‑mutant AML or high‑risk MDS

  This will test whether taking ivosidenib after a recent allogeneic stem cell transplant helps people with AML or high‑risk MDS who have an IDH1 mutation stay in remission longer.

  Recruiting at 14 sites Phase 2 Technische Universität Dresden · Aachen and 16 other locations · NCT06717958

• MT-401-OTS treatment for relapsed AML or high‑risk MDS (safety focus)

  This trial will test whether escalating doses of an experimental off‑the‑shelf cell therapy called MT-401-OTS are safe and can reduce residual disease in adults aged 65 and older with relapsed or persistent AML or high‑risk MDS with low blast counts.

  Recruiting at 3 sites Phase 1 Marker Therapeutics, Inc. · Duarte, California and 2 other locations · NCT06552416

• Using eganelisib alone and with cytarabine for treating relapsed/refractory AML

  This study is testing if a new drug called eganelisib, used alone or with another drug called cytarabine, can help people with relapsed or hard-to-treat acute myeloid leukemia feel better.

  Recruiting at 12 sites Phase 1 Stelexis BioSciences · Duarte, California and 11 other locations · NCT06533761

• CAR T-cell therapy for children with hard-to-treat blood cancers

  This study is testing a new CAR T-cell therapy to see if it can safely help children and young adults with tough-to-treat blood cancers like leukemia and lymphoma.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT06326463

• OURA ring wearable monitoring for adults with myelodysplastic syndromes

  This pilot will test whether adults with MDS can wear an OURA ring regularly and upload biometric data so clinicians can link those measurements with quality of life and transfusion status.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT06270771

• Monitoring residual disease in leukemia patients after stem cell transplantation

  This study is testing a new digital method to see if it can better track leftover leukemia cells in patients after they receive a stem cell transplant compared to older methods.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06211166

• Combination therapy with Venetoclax and Decitabine for relapsed or refractory AML

  This study is testing a new combination treatment of Venetoclax and Decitabine to see if it can help people with newly diagnosed or returning acute myeloid leukemia feel better and achieve remission.

  Recruiting Phase 2 University Hospital Tuebingen · Tübingen, Baden-Wurttemberg · NCT06156579

• Global registry for mitochondrial disorders

  This study is creating a global database for mitochondrial disorders to help understand these diseases better and improve future treatments for patients.

  Recruiting at 34 sites LMU Klinikum · Innsbruck and 33 other locations · NCT05554835

• Using Tagraxofusp to treat pediatric patients with relapsed or refractory blood cancers

  This study is testing a new drug called Tagraxofusp to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.

  Recruiting at 15 sites Phase 1 Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California and 30 other locations · NCT05476770

• Combining Luspatercept with ESA for Low-Risk Myelodysplastic Syndromes

  This study is testing if combining a new drug called luspatercept with existing treatments can help people with low-risk myelodysplastic syndromes who haven't responded to current therapies.

  Recruiting at 31 sites Phase 1/2 Groupe Francophone des Myelodysplasies · Amiens and 40 other locations · NCT05181735

• Comparing precision therapy to standard therapy for elderly patients with AML and MDS

  This study is testing if a personalized cancer treatment based on genetic information works better and is safer for older patients with acute myeloid leukemia and myelodysplastic syndrome than the usual standard treatment.

  Recruiting Phase 2 University Hospital, Akershus · Lørenskog · NCT05025098

• Long-term study of blood diseases in patients in China

  This study is trying to gather detailed information from patients in China with blood diseases like leukemia and multiple myeloma to better understand how these conditions affect their lives and treatment options.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT04645199

• Cord blood transplant for children and young adults with blood cancers and disorders

  This study is testing a new treatment using chemotherapy followed by a cord blood transplant to see if it can help children and young adults with serious blood cancers and disorders who don't have a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT04644016

• Intensity Modulated Total Marrow Irradiation for Acute Leukemia and MDS

  This study is testing a new type of radiation treatment before a stem cell transplant to see if it helps people with acute leukemia or myelodysplastic syndromes do better.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT04187105

• Assessing frailty to improve treatment for older patients with blood cancers

  This study is testing if checking how frail older patients with blood cancers are can help doctors choose better treatments for them.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT03680677

• Investigating genetic factors in childhood cancer

  This study is trying to find out if certain genes passed down in families can increase the risk of childhood cancer by looking at samples from kids who have had cancer and their relatives.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT03050268

• Stem cell transplant for GATA2 mutations

  This study is testing if a stem cell transplant can help people aged 8 to 70 with GATA2 mutations and related conditions feel better and produce healthy blood cells.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01861106

Related topics

Quick answers

How many MDS clinical trials are recruiting right now?

26, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 10 countries. The most sites are in United States (13 trials), China (6 trials), Germany (3 trials), France (2 trials), Italy (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1: 6, Phase 2/3: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →